Ortho Clinical Diagnostics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Ortho Clinical Diagnostics (Nasdaq: OCDX) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, set for January 11, 2022, with a virtual presentation at 9:00 AM ET. The event will be accessible via a live webcast on the company’s website under the 'Investors' section. Ortho Clinical Diagnostics, a leading in vitro diagnostics company, impacts over 800,000 patients daily, providing innovative testing solutions to improve healthcare outcomes globally.

RARITAN, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, with a virtual presentation scheduled for 9:00am ET.

Interested parties can access a live webcast and replay of the presentation on the “Investors” page of the company’s website at https://ir.orthoclinicaldiagnostics.com/, under the “Events” section of the page.

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test Is A Life^TM, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate and reliable. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.

From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology, and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years.

The company is powered by Ortho Care^® Service and Support, an award-winning, holistic program that ensures best-in-class technical, field, and remote service and inventory support to laboratories in more than 130 countries and territories around the globe.  

For more information, visit Ortho’s social media channels: LinkedIn, Twitter, Facebook and YouTube. 

FAQ

When is the J.P. Morgan Healthcare Conference presentation for OCDX?

The presentation is scheduled for January 11, 2022, at 9:00 AM ET.

How can I access the OCDX presentation from the J.P. Morgan Healthcare Conference?

The presentation can be accessed via a live webcast on the 'Investors' page of Ortho Clinical Diagnostics' website.

What is the significance of Ortho Clinical Diagnostics in the IVD sector?

Ortho Clinical Diagnostics is a major player in the in vitro diagnostics space, impacting over 800,000 patients daily with innovative testing solutions.

What innovative technologies does OCDX provide for patient care?

OCDX offers rapid and accurate testing solutions that enhance clinical outcomes and improve laboratory efficiency.

How long has Ortho Clinical Diagnostics been a leader in the IVD field?

Ortho Clinical Diagnostics has been a pioneering leader in the in vitro diagnostics field for over 80 years.